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ABSTRACT
Rheumatoid arthritis (RA) is a chronic disease related to swelling of joints which lead to restriction in movement due to pain and deformity mainly in 
feet, ankle, wrist, and fingers. It is an autoimmune disease, and the manifestations caused due to its occurrence are not clearly understood. In today’s 
time, it has been observed that comorbid conditions account for most of the deaths as they influence the outcome of RA and limit therapeutic options. 
The most common comorbid conditions which are diagnosed in RA patients are generally cardiovascular (CV) abnormalities, several infections, 
certain mental disorders, and malignancies. Among which CV comorbid diseases are the most common kind relating to disorders of heart and blood 
vessel that eventually leads to severe conditions such as angina, myocardial infarction, stroke, rheumatic heart disease, and many more. RA affects 
the quality of life of patients directly or indirectly, but it mainly shows a significant increase in the prevalence of CV diseases. Hence, it is essential 
to diagnose and understand about the related manifestations when one is suffering from RA. These studies will aid to make better treatment and 
management strategies. Hence, an attempt has been made in this review article regarding the epidemiology, impact of both diseases and related 
risk factors. It also gives information in brief about the pathological causes of the comorbidity and summarizes measures that may be used in the 
prevention and treatment of these conditions.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, incurable disease characterized 
primarily by painful joint inflammation [66]. Comorbidity is a medical 
condition that co-exists along with the disease of interest for instance. 
RA comorbidity can be further defined in terms of a current or past 
condition. It represents either an active, past or transient illness. 
It may be linked to the rheumatic disease process itself and/or 
its treatment, or it may be completely independent. Due to these 
links, comorbidities have grown in importance to physicians and 
researchers because they greatly influence the patient’s quality of 
life, the effectiveness of treatment, and the prognosis of the primary 
disease. A given RA patient can approximately have 1.6 comorbidities 
and its frequency increases with increase in age. The more 
comorbidities a patient is identified with, it leads to more utilization 
of health facilities which has an impact not only on personal costs but 
also escalates societal costs. Ultimately, poor quality of life leads to 
greater chances of hospitalization and mortality. Such complications 
affect patient care, making diagnosis and treatment decisions more 
challenging. If presence of co-morbidity is more than one is prone 
towards more interference in on-going drug treatment and also face 
problems like increased medical costs and raised risk of mortality. 
Hence, it is essential to recognize such illnesses and to ensure the care 
of every individual patient [1].
Patients with RA suffer significantly with increased cardiovascular (CV) 
morbidity and mortality when compared with the general 
population [2]. CV diseases (CVD) are the ones relating to disorders of 
heart and blood vessel which lead to severe conditions such as angina, 
myocardial infarction (MI), stroke, rheumatic heart disease, carditis, 
and many more [3,4].
17.5 million people die each year from CVDs, an estimated 31% of all 
deaths worldwide. It can be established from recent literary work that 
the mortality of most people suffering from RA is largely due to the 
presence of a cardiac suffering in the same individual. Ischemic heart 
disease is among the most common CVDs significantly in individuals 
with RA [3,4]. Improper adherence to medications is also major 
patients’ problem remains one of the main issues in the treatment of 
CVD problem like hypertension [65].
As per described previously the other comorbid disorders with RA are 
as follows:
Infections
Tuberculosis (TB) is the most common infection which is prone to 
occur in RA patients. Mortality rate associated due to this infection 
is about 25% in RA patients. Cause of this disease arousal is still not 
known whether it is due to immune dysfunction of RA patient or due 
to drugs used in treating individual infection or both diseases [57,60].
Mental disorders
Anxiety and depression are the most common mental diseases as 
such reason behind is generally increased disease condition in RA 
patients [61,64].
Malignancies
Leukemia and several myelomas have greater chances to arise in RA 
patient, but the reason behind this malignancy is still unknown [60].
STUDY EVIDENCE
The latest population-based study carried out compares RA and non-
RA subjects and suggests that those with RA show a 3.17-fold higher 
risk for having hospital MI and an almost 6-fold increased risk of having 
a silent MI. Thus, the data expresses a progressive incidence of silent MI 
and of sudden death after its occurrence [5].
EPIDEMIOLOGY OF COMORBIDITY OF CVDS AND RA
As per the survey report of community-based cohort study which was 
carried out form the period of 1985-1989, among 183 patients with 
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age of 52 years, concentrating more on female population (63%), were 
diagnosed with the early RA. The study included continuous recording 
of additional comorbidities along with RA. The results of the same 
stated that along with RA diagnosis, at least one comorbidity was 
present in 43% of the patients. The comorbid conditions like CVDs, 
including hypertension (16% of patients), stroke, and malignancy, were 
found to be most common, among which majority of patients (82%) 
developed additional comorbidities during their follow-up treatment. 
It was predicted from the cohort study that aging of the population 
and the presence of comorbidity along with RA was the cause for the 
development of comorbidities [5].
Again in 2000 and 2007, a similar cohort study was conducted 
which stated 1383 (19.2%) of patients in total were diagnosed with 
hypertension as a comorbid condition along with RA. The study reported 
the result in terms of prevalence which was found to be 20% in men 
were as 18.8% in women out of 465 cases and 918 cases, respectively. 
The prevalence of chronic hypertension among the RA population did 
not exist in the rheumatoid factor (RF)-positive subgroup. However, 
there was increased risk of development of chronic hypertension in the 
RF-negative subgroup [5].
Another study conducted for the study of prevalence of the 
comorbid conditions, i.e., the comorbidities in RA (COMORA) study 
which had two major objectives were conducted for the same. The 
first objective was evaluation of the variability in the prevalence 
of comorbidities and their risk factors. The second objective was 
assessment of distinctive national treatment recommendations 
between the already existing ones and its implementation in routine 
clinical practice for the detection and prevention of these developing 
comorbidities [7].
The majority of periodically associated diseases either past or current 
were found to be: 6.6% of CV events which included MI, stroke, and 
elevated blood pressure in a patient population of 11.2% with RA. 
There was high intercountry variability observed for the prevalence of 
comorbidities and the proportions of the candidates subjected to the 
study, complying with the treatment recommendations for prevention 
and management of these comorbidities [6].
A systemic evaluation of comorbidities in COMORA study observed 
abnormalities like elevated blood pressure in 11.2% which identified 
conditions of hyperglycemia in 3.3% and hyperlipidemia in 8.3% cases 
under the study [6].
Thus, the study concluded that the higher death rate appeared as the 
consequences due to an increased prevalence of CV risks, an increased 
incidence of infections, and the development of certain malignancies in 
patients with RA [7,8].
IMPACT OF RA ON CVD
Awareness is already there regarding arthritis affecting body joints 
but unfair or unaware news is such that arthritis is also responsible 
for causing several CV disorders such as heart attack, atrial fibrillation, 
atherosclerosis, and high blood pressure. As per the nature reviews 
rheumatology more than about 50% death is observed in a patient of 
RA due to heart diseases. Inflammation regardless is a troublemaking 
disorder causing heart disease. In this, the inflamed cells get into the 
blood vessels where they cause increase in the release of cytokines 
and serum proteins which in turn promote more inflammation. This 
inflammation also leads in rupturing of deposited plaques on blood 
vessels which proves to be a triggering factor responsible for causing 
heart attack as per arthritis and rheumatism review inflammation does 
not act alone but it is found to be acting in increased amount in patients 
who are having heart disease risk factors in addition to it, like high 
blood pressure or diabetes or atherosclerosis.
Risk factors
•	 According	to	Figs.	1	and	2,	smoking	may	increase	level	of	nicotine	
which in turn leads to increase in chances of heart failure




•	 Overweight	 is	also	 that	 solely	 responsible	 for	CVD	and	condition	
may even get worse if proper exercise is not being done long with a 
regular diet plan.
As per a disease control committee, there have been some ratios 





Hence on the basis of a survey made about one-fourth adult with 
any arthritis form has heart disease. Thus, concluded as per one of 
the review author along with a reduction in CV risk, inflammation is 
required to be reduced too with habitual risk factors such as blood 
pressure, diabetes, high lipids, and smoking.
IMPACT OF CVDS ON RA
CVDs are found to be highly prevailing in RA patients and they 
contribute significantly in raising morbidity and mortality rates 
[51]. In the case of RA patients they are considered to be as a kind 
of clinical manifestation. As a part of recent findings silent MI in 
RA patients as comorbidity leads to death of the patient because of 
certain known risk factors such as damaged peripheral blood vessels 
gets revascularized and also certain genetic abnormalities [21]. The 
CV impact on RA at certain extent is still considered to be unknown 
and it is under core observation. Several heart patients along with 
this disorder are having rheumatism which proves to be an elevator 
in causing an increase in comorbid activity. Awareness, in this case, is 
must before its expansion.
Risk factors
•	 Decreased	exercise	may	be	one	of	the	reasons	for	manifesting	CVD	
in rheumatic patients due to reduction in mobility
•	 Fluid	retention	may	be	responsible	for	its	spread	in	different	areas	
of the body and also affects vital organs too.
Because of resting in heart patients it may also result in occurrence 
of edema and swelling particularly in legs, feet and the ankles due to 
prolonged sitting pitting edema occurrence is also due pressing of 
puffy areas that are being inflamed. It mainly affects liver and kidney 
not synonymous to heart failure [9]. This swelling due to heart disease 
may also reach to hips, scrotum, abdominal wall, and eventually 
abdominal cavity. Hence, daily weight checkup is required to be done 
by the heart patients because the amounts of fluid retention in turn 
either result into joint pain or increase in shortness of breath. Thus, 
strict diet program and exercise program to be followed up. In short 
clinical manifestations of both RA and CVDs are linked with each 
other [9].
CLINICAL PRESENTATION
There lies a close correlation between the morphology of progressive 
carotid atherosclerosis and inflammation, which insinuates 
elevations in inflammatory biomarkers which indicate occurrence of 
atherosclerosis [20]. Specific systemic inflammatory biomarkers show 
a remarkable increase in the risk of CV death in patients with RA [21,22]. 
A substantial increase in the levels of proinflammatory mediators such 
as	 tumor	necrosis	 factor-alpha	 (TNF-α),	 interleukin	 (IL-6),	 and	 IL-17	
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damage the endothelium as well as the myocardium which predisposes 
insulin resistance [23-25,38,39]. C-reactive protein (CRP) at minimal 
level acts as an essential indicator of subsequent death from CVD in 
patients with recent onset of arthritis [26]. High concentration of CRP 
indicates increased carotid media thickness [27].
Some clinical features such as higher erythrocyte sedimentation rate, 
rheumatoid nodules, vasculitis, large joint swelling, and rheumatoid 
lung are independently correlated with increased risk of death due to 
CVD [21].
A modern study compares individuals with RA and controls which 
showcased	 association	 of	 TNF-α	 and	 IL-6	 with	 the	 complexity	 of	
coronary artery calcification occurring in RA. Increased stiffness of 
arteries occurring in RA can be well correlated with CRP and IL-6 
levels [26]. In patients with new onset of congestive heart failure, 
high sedimentation rate was found in 6 months preceding the 
detection of cardiac dysfunction which indicated that an enhanced 
inflammatory pathogenesis may lead to cardiac dysfunction due 
to inflammatory arthritis [31-34]. The extent and chronicity of 
inflammatory processes were measured with the circulating levels of 
inflammatory biomarkers and was linked to carotid atherosclerosis 
development in RA [27]. The overall amount of adhesion molecules 
such as soluble vascular cell adhesion molecule-1 (VCAM-1), 
intercellular adhesion molecule-1, and endothelial–leukocyte 
adhesion molecule related to vascular damage were higher in RA. 
VCAM-1 levels have been correlated with carotid atherosclerosis in 
individuals with RA [28].
The exact role of IL-17 in premature vascular damage in RA is 
believed to be unraveled; a recent research indicated that cytokines 
play a major role in atherosclerosis development in murine models 
of vascular diseases [32,33]. This study also reported elevated 
circulating level of IL-17 in cases with acute coronary syndrome 
[34].	 IL-17	 is	 produced	 along	 with	 interferon-γ	 INF-γ	 by	 coronary	
artery infiltrating T-cells. These cytokines act synergistically to cause 
proinflammatory responses in vascular smooth muscles [35]. IL-17 
also showed an increase in myocardial fibrosis in animal models 
having heart injury [36]. Thus, many evidences are collected that 
support the fact that IL-17 plays a regulatory role in the development 
of atherosclerosis [37].
Inflammatory biomarkers
RA and CVD have a common inflammatory mechanism. Specific 
systemic inflammatory biomarkers such as IL-6, IL-17, and TNF which 
are elevated in RA are well correlated with increased risk of CV death 
in patients [24,38].
Revelation of proatherogenic lipid profile
A recent study between 87 women with RA and with 50 healthy ones 
revealed a proatherogenic profile in women with RA. Lipoprotein A was 
considerably increased, and high-density lipoprotein cholesterol was 
found to be decreased in them [24,39].
Metabolic abnormalities
One study involving 154 cases of RA showed a high prevalence of 
metabolic syndrome. Insulin resistance was observed due to an 
alleged increase in oxidative stress as well as over expression of 
pro-inflammatory cytokines [40].
Genetic association
Many genetic links have been established for the comorbidity of CVD and 




Cellular level changes can induce CVD in patients already suffering 
with RA. Exceeding population of CD4+CD28− T-cells in such 
individuals generally predisposes atherosclerotic plaques and unstable 
angina [45].
EXTRA-ARTICULAR SYMPTOMS OF RA
An epidemiological research linked few extra-articular manifestations 
of RA such as rheumatoid nodules, vasculitis, and rheumatoid lung with 
increased risk of CV death in patients [46].
As per a survey data internationally the prevalence of RA is believed 
to range from 0.4 to 1.3% [52,53] also on the basis of Rochester 
Epidemiology Project it was found that there was increase in RA 
among female individuals annually and comparatively reduction of 
about 0.5% was found in male individuals [54]. Life time risks as per 
that epidemiology report were estimated about 4% in female and 3% 
in male [55]. Multiple studies reported that in the past half century 
with diagnosed RA has increased mortality rates compared to the 
general population [56]. It was also reveal regarding the comorbid 
disorders among which ischemic heart diseases were diagnosed 
too in patient with RA [56]. People with RA have greater evidence of 
atherosclerosis [57] and risk of silent MI [58] too. A 2015 study found 
that risk of CVD rose [59]. It is unknown whether the increase in CVD 
mortality is due to the disease, the risk factors found in people with 
RA (e.g., presence of hypertension, more likely to be smokers), or the 
effects of the drugs used to improve the health condition [58,60].
WORSENING DUE TO COMORBIDITY
Patients are more prone for the development of chronic comorbid 
disorder on the basis of age as well as gender. Of the main diseases 
group CVDs were developed as a new comorbid disorder. These 
diseases might develop after a longer period than our median follow-
up duration of nearly 3 years. The patient may also experience 
reduced life expectancy and increased mortality even though there 
has been reduction in disease. There is about 70% increase in death 
rate as a risk factor of CVD in arthritis. Out of which is 5-10% in men 
Fig. 1: Basic steps to reduce the risk of comorbidity
Fig. 2: Treatment algorithm for comorbidity
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and 2-4% in women aged 50-67 years [12]. It has also been found 
that patient with RA along with diabetes are less prone for developing 
angina but they are more susceptible in getting MI attacks and even 
sudden cardiac deaths. Possibilities of getting recurrent ischemic 
attacks are also more in rheumatic patients. Patient with RA if is 
having comorbidity of CVD along with it also has a higher rate of 
getting suffered from depression. Studies have also found that pre-
clinical atherosclerotic attacks are also found in RA patient. Confusion 
still exists regarding preventive measures to be taken in CV risks. Even 
uncertainty is at its peak regarding how RA to be treated along with 
avoidance of future CV risks as some medications used in RA might 
have dual effect on the risk of CV morbidity. As an example steroids 
might decrease CV risks along with its reduction in inflammation 
but in turn it also causes elevation in proatherosclerotic lipid profile 
levels. Hence, these accelerated elevating CV complications along 
with RA are considered to be complex. Overall, studies have finally 
discovered that this increasing CV complications and mortality in RA 
must be provided with proper treatment in which traditional and 
non-traditional risks factors are of topmost importance in patient 
population [13].
TREATMENT OF COMORBIDITY
The recommended treatment for the comorbid condition following 
arthritis medications which offers heart protective benefits.
Treatment with tumor necrosis factor-alpha inhibitors
A recent study in 2011, which was published in the Annals of Rheumatic 
Diseases, observed that patients under these biologics, such as 
etanercept, infliximab or adalimumab had a reduced risk of developing 
heart disease. Another study of Johns Hopkins in the same year observed 
that	 the	patients	with	RA,	when	administered	with	TNF-α	 inhibitors,	
had a lower rate of thickening in their carotid arteries approximately 
37% than those not consuming it. A survey study published in the 
American Heart Journal observed that, in the elderly patients with RA, 
TNF-α	inhibitors	elevated	the	risk	of	heart	failure	as	it	was	very	clearly	
distinguished between the effect of these biologics on the heart muscles 
and on the arteries [10].
Treatment with methotrexate
Methotrexate is a disease-modifying antirheumatic drug (DMARD) 
which is considered as the first line agent and often given to patients 
with RA. Evidence-based British review in 2010 comprising 18 studies 
was published in Rheumatology, observed that patients with RA taking 
methotrexate had reduced chances of developing a heart. “A large 
amount of research shows that methotrexate can reduce the risk of 
heart disease,” through the reduction in the plaque accumulation in the 
arteries [10].
Treatment with hydroxychloroquine
An evidence British review which was conducted in 2011 and published 
in Current Opinions in Lipidology observed that hydroxychloroquine 
worked on improving the risk factors associated with heart diseases 
such as blood sugar and cholesterol levels. The study also concluded 
that the effect of this biologic on the reducing risk factors associated 
with heart diseases was still under the study [10].
CURRENT RECOMMENDEDATIONS FOR TREATMENT OF 
COMORBIDITY
RA is a chronic inflammatory disease. RA sufferers along with chronic 
inflammatory condition they too suffer from CVD as comorbid 
disorder and prevalence of mortality rate is also higher due to this in 
RA patients [14] hence the current recommended medication for this is 
TNF-α	blocker	(TNF-α	antagonist).
TNF-α mechanism
Initial stimulus for joint inflammation activates macrophages which in 
a	diseased	joint	secrete	TNF-α,	which	activates	some	endothelial	cells,	
other monocytes, and synovial fibroblasts. Activated endothelial cells 
upregulate adhesion molecule expression, resulting in recruitment 
of inflammatory cells to the joint. Monocyte activation has a positive 
feedback effect on T-cell and synovial fibroblast activation. Activated 
synovial fibroblasts secrete interleukins, which recruit additional 
inflammatory cells. With time, the synovium hypertrophies lead to 
destruction of bone and cartilage in the joint, causing the characteristic 
deformity and pain of RA [48].
This anti-TNF is given which generally causes decrease in the activity by 
reducing	 systemic	 and	 local	 inflammation	 [15].	 This	TNF-α	 antagonist	
eventually decreases unfit coagulation and CV risk associated with 
RA. Anti-TNF role in thrombotic mechanism as per the evidence so far 
available indicates it can modify CV risks which are associated along with 
RA [14].
NATURAL TNF BLOCKERS
Mechanism of curcumin (a compound present in turmeric): Turmeric 
supplements containing curcuminoids lessen joint inflammation 
and its destruction by blocking several inflammatory pathways and 
simultaneously reduce production of certain proteins which in turn 
triggers pain. It has been found that it has its influence on more than 
700 genes, and it can inhibit both excessive activity and the synthesis of 
cyclooxygenase-2 (COX-2)and 5-lipoxygenase, as well as other enzymes 
that have been implicated in inflammation [15,49].
Mechanism of catechins (a compound present in green tea): Catechins 
from green tea are effective in rheumatism. Two types of catechins 
such as epicatechin gallate and epicatechin are having activity of anti-
inflammatory along with protecting the cartilage destruction. This is 
found to be a unique activity of catechins. Hence as per the study, it 
has been proved that green tea contains catechins which prevent and 
protects the cartilage from getting destroyed [15,50].
Even activation of cannabinoid receptors, i.e., CB1 or CB2 by usage 
of cannabis or Echinacea purpurea shows their activity of anti-
inflammatory	by	TNF-α	inhibition	[15].
Adverse effects
These natural anti-inflammatory agents are found to have maximum 
advantages and the highest improving features of reducing joint 
inflammation along with protecting cartilage destruction. Safest 
prescribed medications with zero adverse effects [49].
SYNTHETIC TNF BLOCKERS
Mechanism
They are determined to be a type of biologic DMARDs. These agents are 
a group of novel therapeutics based on recent advances. Main activity 
is	 these	 TNF-α	 antagonist	 bind	with	 TNF-α	 in	 circulation	 of	 synovia	
region and neutralizes it that is reducing its inflammatory activity. They 
also control activity of osteoclasts and also osteoclast genesis thereby 
inhibiting joint destruction.
Adalimumab
It is a fully human anti-tumor necrosis factor-alpha monoclonal 
antibody which is produced by phage display technology [16,51].
Infliximab
This drug is 25% mouse derived and 75% human. The binding epitope 
for TNF is of mouse origin while the immunoglobulin G fragment is 
human based [16,51].
Golimumab
Approved for moderate to severe arthritis [16,51].
Tocilizumab is the commonly used synthetic TNF blockers [16].
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Adverse effects
Injection site reaction, several allergic reactions, increased risk of 
infections such as TB and fungal, neurological disorders, increase in 
lymphoma and skin cancer, possible worsening of heart disease [51].
OTHER THERAPIES IN COMORBIDITY
Other therapies include anti-RA drugs, nonsteroidal anti-inflammatory 
drugs (COX-2 inhibitors), steroidal anti-inflammatory drugs 
(glucocorticoids), and disease modifying anti-rheumatoid drugs 
(methotrexate) [18,19].
Along with these medications, lifestyle modifications also add on 
reduction in risks associated with the comorbid disorders. Smoking 
cessation, blood pressure and cholesterol control, blood sugar kept 
within the safe range, weight control, diet, exercise helps to achieve 
all these goals for proper and maintained health conditions. In the 
case of inflammation due to RA and in contribution CV risk also 
persists it can be lowered using proper RA medications which can 
dramatically decrease CV abnormalities. Through one study it has 
been found that use of DMARDs in RA patients can reduce CV risks 
too about 60-70%.
CONCLUSION
CVD as per above discussion is being one of the reasons of death 
in RA patients and mortality rate is nearly about 40%. Patients with 
RA from 10 years or more are at a 2-fold increased risk for MI and 
stroke. Congestive cardiac failure leads to excess mortality cases than 
myocardial ischemia. Dyslipidemia, insulin resistance, prothrombotic 
state, hyperhomocysteinemia, and immune mechanisms as T-cell 
activation subsequently lead to endothelial dysfunction which causes 
arterial stiffness, as an analog of causing accelerated atherosclerosis 
in RA patients. Eventually, it’s concluded RA is having a major and 
greater effect on CV in terms of disease rate and also on the basis of 
its mortality rate which is found to be increasing along with upcoming 
days. As per a researcher diagnosis of patients with RA should be done 
with time to address potential heart risks in the future [19]. Concluding 
as such comorbid diseases are having a great impact on life as well as 
on treatment itself, so in that case defensive care should be our main 
treatment spot.
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